New Research on TMS, 2026
Recent 2026 research in transcranial magnetic stimulation (TMS) highlights major
advancements in how to apply transcranial magnetic stimulation. We are happy to offer TMS as
a treatment to our patients with major medical depression (MMD) that has proven difficult to
treat via other methods.
Precision targeting in TMS moves beyond standard generalized scalp measurements (such as
the 10-20 EEG system, F3/F4, or the 5.5 cm rule) to tailor coil placement to an individual’s
unique brain anatomy and functional networks.
An accelerated TMS (Transcranial Magnetic Stimulation) protocol condenses a standard 4-to-8-
week course of brain stimulation into just a few days or one week by delivering multiple
treatment sessions per day.
Here’s how that works:
− Frequency: Instead of 1 session per day, accelerated protocols typically deliver 4 to 10
short sessions per day.
− Duration: Individual sessions use intermittent theta-burst stimulation (iTBS) or rapid
pulse patterns, lasting anywhere from 3 to 10 minutes per session.
− Timeline: Total treatment courses span roughly 5 to 10 days (such as the Stanford
Neuromodulation Therapy / SAINT protocol or cleared Deep TMS protocols), compared
to traditional 30-to-40-session schedules.
TMS research has also seen advances in circuit-specific and precision targeting using
dorsomedial and dorsolateral prefrontal cortex use. Harvard researchers demonstrated that
while standard targets (dorsolateral prefrontal cortex) and novel targets (dorsomedial
prefrontal cortex) both ease depression, intentional targeting of distinct brain circuits
selectively improves specific anxiosomatic symptoms like irritability, insomnia, and sexual
disinterest via the Harvard Gazette.
We are keeping close tabs on how to combine TMS with other psychotherapy options. Studies
on combat veterans with PTSD showed that navigated TMS paired with psychotherapy achieved
significant symptom relief in 85% of patients within a month compared to 60% with sham
treatment. Additionally, Wave Neuroscience reported a 52% reduction in PTSD symptoms with
a 68% remission rate in recent findings published via ScienceDaily.
Another way that TMS is being expanded is centered on accelerated protocols and at-home
therapy on a condensed schedule. Research indicates that daily 6-to-8-week sessions can be
compressed using prolonged intermittent theta burst stimulation (iTBS) and multiple daily
sessions, though insurance and Medicare reimbursement largely remain capped at lower
session counts. In January 2026, the FDA approved Prolieve, the first prescription, physician-
directed at-home brain modulation therapy for major depressive disorder (MDD) that stimulates nerve branches above the forehead.
TMS shows expanded conditions in the quality of life for patients, as well as decreasing
suicidality in youth and adults. Clinical trials tracking 10 Hz and 1 Hz TMS in adolescents (ages
12–18) and older adults showed meaningful reductions in suicidal ideation and high rates of
depression remission. Patient-reported quality of life metrics 12 weeks post-TMS revealed that
normal quality of life measures jumped significantly (from under 3% prior to treatment to
roughly 24–27% post-treatment across age groups).
Substance use and neuroplasticity techniques are being used to target specific areas like the
superior frontal gyrus (SFG) to maximize smoking craving reductions, and ongoing work
explores TMS for post-stroke motor recovery using portable adaptive brain-computer interfaces
as outlined by Nature.
For questions and appointments, write to us on our website or call (585) 442-6960.
